Jump to content

Pliva

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 21:58, 20 May 2020 (Dating maintenance tags: {{Cn}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pliva d.o.o.
Company typeSubsidiary
IndustryPharmaceutical industry
Founded1921; 103 years ago (1921)
HeadquartersZagreb, Croatia
Key people
Mihael Furjan, CEO
ProductsGeneric drugs
Revenue$1.174 billion (2005)
$0.336 billion (2005)
Number of employees
1,700
ParentTeva Pharmaceuticals
Websitewww.pliva.com
Footnotes / references
[1]
Pliva headquarters in Zagreb
Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics.

Pliva d.o.o. is a pharmaceutical company based in Zagreb, Croatia that primarily manufactures and sells generic drugs. It is a subsidiary of Teva Pharmaceuticals.

Pliva is one of the world's largest producers of generic Adderall.[citation needed]

History

The company was founded in 1921.[1]

A team of Pliva's researchers, Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski and Zrinka Tamburašev led by Dr. Slobodan Đokić, discovered azithromycin in 1980.

In June 2002, the company acquired Sidmak for $152.9 million.[2]

Also in June 2002, Zeljko Peric, the chief financial officer of the company, resigned.[3]

In May 2004, the company received approval from the Food and Drug Administration to sell trospium chloride.[4]

In June 2005, the company received approval to sell a generic version of erythropoietin in Croatia.[5]

In November 2005, the company received approval from the Food and Drug Administration to sell a generic version of Azithromycin,[6] Citalopram,[7] and Ondansetron.[8]

In October 2006, Barr Pharmaceuticals acquired Pliva.[9]

On December 23, 2008, Barr Pharmaceuticals was acquired by Teva Pharmaceuticals and the company became part of Teva Active Pharmaceutical Ingredients (TAPI).[10]

References

  1. ^ a b "Company Profile". Pliva.
  2. ^ "PLIVA announces acquisition of US-based Sidmak" (Press release). Pliva. June 11, 2002.
  3. ^ "PLIVA announces management changes" (Press release). Pliva. June 27, 2002.
  4. ^ "PLIVA Announces FDA Approval of SANCTURA" (Press release). Pliva. May 31, 2004.
  5. ^ "PLIVA Registers generic EPO in Croatia" (Press release). Pliva. June 21, 2005.
  6. ^ "PLIVA Announces Approval for Azithromycin Tablets" (Press release). Pliva. November 15, 2005.
  7. ^ "PLIVA Announces Approval for Citalopram Hydrobromide Tablets" (Press release). Pliva. November 3, 2005.
  8. ^ "PLIVA Announces Approval for Ondansetron Hydrochloride ODT" (Press release). Pliva. November 21, 2005.
  9. ^ "Barr Acquires PLIVA d.d." (Press release). Pliva. October 12, 2006.
  10. ^ "TEVA COMPLETES ACQUISITION OF BARR" (Press release). Pliva. December 23, 2008.